PHENOMEX INC (CELL)

US0843101017 - Common Stock

0.9981  +0 (+0.31%)

After market: 0.999 +0 (+0.09%)

Fundamental Rating

3

Taking everything into account, CELL scores 3 out of 10 in our fundamental rating. CELL was compared to 56 industry peers in the Life Sciences Tools & Services industry. The financial health of CELL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CELL is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CELL had negative earnings in the past year.
In the past year CELL has reported a negative cash flow from operations.
In the past 5 years CELL always reported negative net income.
CELL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CELL's Return On Assets of -69.85% is on the low side compared to the rest of the industry. CELL is outperformed by 92.19% of its industry peers.
With a Return On Equity value of -111.90%, CELL is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROIC N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CELL's Gross Margin of 64.75% is amongst the best of the industry. CELL outperforms 89.06% of its industry peers.
In the last couple of years the Gross Margin of CELL has declined.
The Profit Margin and Operating Margin are not available for CELL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CELL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CELL has been increased compared to 1 year ago.
Compared to 1 year ago, CELL has a worse debt to assets ratio.

2.2 Solvency

CELL has an Altman-Z score of -3.61. This is a bad value and indicates that CELL is not financially healthy and even has some risk of bankruptcy.
CELL has a Altman-Z score of -3.61. This is amonst the worse of the industry: CELL underperforms 85.94% of its industry peers.
CELL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.61
ROIC/WACCN/A
WACC11.88%

2.3 Liquidity

A Current Ratio of 2.25 indicates that CELL has no problem at all paying its short term obligations.
CELL has a Current ratio of 2.25. This is in the lower half of the industry: CELL underperforms 70.31% of its industry peers.
A Quick Ratio of 1.26 indicates that CELL should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.26, CELL is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.26

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CELL have decreased by -9.52% in the last year.
Looking at the last year, CELL shows a very negative growth in Revenue. The Revenue has decreased by -17.32% in the last year.
CELL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.51% yearly.
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%

3.2 Future

Based on estimates for the next years, CELL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.95% on average per year.
Based on estimates for the next years, CELL will show a very strong growth in Revenue. The Revenue will grow by 20.33% on average per year.
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CELL's earnings are expected to grow with 21.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.78%
EPS Next 3Y21.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CELL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHENOMEX INC

NASDAQ:CELL (9/29/2023, 8:22:41 PM)

After market: 0.999 +0 (+0.09%)

0.9981

+0 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-06 2023-11-06/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner Change0%
Market Cap98.79M
Analysts50.91
Price Target1.53 (53.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.91%
Min EPS beat(2)-4.8%
Max EPS beat(2)-1.01%
EPS beat(4)0
Avg EPS beat(4)-15.27%
Min EPS beat(4)-49.99%
Max EPS beat(4)-1.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.51%
Min Revenue beat(2)-20.56%
Max Revenue beat(2)1.55%
Revenue beat(4)1
Avg Revenue beat(4)-12.68%
Min Revenue beat(4)-28.89%
Max Revenue beat(4)1.55%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.73
BVpS1.12
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.53%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.26
Altman-Z -3.61
F-Score3
WACC11.88%
ROIC/WACCN/A
Cap/Depr(3y)145.66%
Cap/Depr(5y)157.52%
Cap/Sales(3y)11.31%
Cap/Sales(5y)14.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%
EBIT growth 1Y-16.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.51%
EBIT Next 3Y18.4%
EBIT Next 5YN/A
FCF growth 1Y-50.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.31%
OCF growth 3YN/A
OCF growth 5YN/A